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Abstract
Background: Currently, there is no adequate animal model to study the detailed molecular
biochemistry of fragile X syndrome, the leading heritable form of mental impairment. In this study,
we sought to establish the use of immature neural cells derived from adult tissues as a novel model
of fragile X syndrome that could be used to more fully understand the pathology of this
neurogenetic disease.
Methods: By modifying published methods for the harvest of neural progenitor cells from the
post-mortem human brain, neural cells were successfully harvested and grown from post-mortem
brain tissue of a 25-year-old adult male with fragile X syndrome, and from brain tissue of a patient
with no neurological disease.
Results: The cultured fragile X cells displayed many of the characteristics of neural progenitor
cells, including nestin and CD133 expression, as well as the biochemical hallmarks of fragile X
syndrome, including CGG repeat expansion and a lack of FMRP expression.
Conclusion: The successful production of neural cells from an individual with fragile X syndrome
opens a new avenue for the scientific study of the molecular basis of this disorder, as well as an
approach for studying the efficacy of new therapeutic agents.
Background
Fragile X syndrome, the leading heritable form of mental
impairment [1,2], is generally caused by the expansion of
a trinucleotide (CGG) repeat element in the fragile X men-
tal retardation 1 (FMR1) gene to greater than 200 repeats
(full mutation) [3]. Such expansions generally lead to
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methylation-coupled gene silencing [4,5] and the conse-
quent absence of the FMR1  protein (FMRP), an RNA-
binding protein that is important for neural development
and plasticity [6,7].
Although great strides have been made from animal mod-
els in our understanding of the neuropathology of fragile
X syndrome [8-13], there is, at present, no adequate ani-
mal or cell model to study the detailed molecular bio-
chemistry of the FMR1 gene. The absence of a suitable
model system is a consequence of the inability to clone
full mutation alleles, and because no animal system has
been found that carries native, full mutation FMR1 alleles.
Thus, all animal or cell model systems for fragile X syn-
drome are based on FMR1  (homolog) knock-out con-
structs. While these models qualitatively recapitulate
some of the features of the fragile X syndrome phenotype,
they do not address any of the potential consequences of
the expanded methylated CGG repeat.
As with most disorders of the human nervous system, it
has been impossible to directly study the detailed cellular
pathogenic mechanisms that underlie fragile X syndrome,
due to the absence of a suitable (human) cell model.
However, this barrier may be overcome through the use of
neural progenitor cells, which comprise relatively undif-
ferentiated populations of cells in the central nervous sys-
tem (CNS) that give rise to the broad array of specialized
cells, including neurons and glial cells. Long thought to be
an exclusive component of the developing CNS, these
cells have been shown to exist in the adult CNS [14-19].
Recent research, demonstrating that these cells can be iso-
lated and cultured [14,18,20-22] has raised the prospect
of using neural progenitor cells as a human cell-appropri-
ate (neuronal and astrocytic) model system for the
detailed study of the molecular biology of fragile X
syndrome.
Importantly, we have previously shown that neural pro-
genitor cells can be harvested from adult post-mortem
brain tissue [18,20], which represents a singular advan-
tage over the use of neural stem cells from fetal sources. In
particular, since there is a broad spectrum of clinical
involvement in fragile X syndrome [2], the study of neural
stem cells from individuals of known phenotype provides
us with a closer coupling of the genotype with the clinical
phenotype.
In the current report, we describe the successful culturing
of neural progenitor cells from an adult male with fragile
X syndrome, and some of the characteristics of these cells.
We further demonstrate initial efforts to differentiate
these progenitor cells into both neuronal and astrocytic
lineages. As expected, expression of FMRP is substantially
reduced relative to its expression in neural cell culture
from an unaffected control.
Methods
Autopsy, brain harvest, and tissue cryopreservation
Prior to tissue acquisition by the authors, informed con-
sent for the donation of tissues was obtained under the
auspices of the protocol for the National Human Neural
Stem Cell Resource. This protocol is approved by Institu-
tional Review Board (IRB) of Children's Hospital of
Orange County, and follows a protocol approved by the
UC Davis School of Medicine IRB. All tissues were
acquired in compliance with NIH and institutional guide-
lines. Two patients were used for the present study: a
patient with fragile X syndrome and a patient with no
neurogenetic disease.
The autopsy followed standard procedures as described
[20]. The periventricular zone in the area of the head of
the caudate nucleus regions was identified and dissected
from the appropriate brain sections. Brain region speci-
mens were then placed in separate Petri dishes and rinsed
three times with DGA (see below). Tissues were minced
with sterile scalpel blades, triturated in DGF (see below)
containing 10% DMSO, taken to -80°C overnight in con-
trolled-rate freezing containers, and then transferred to
liquid nitrogen Dewars for long term storage.
Pathology
Portions of fresh brain, heart, and testicular tissue were
received, and fixed in 10% formalin for 10 days prior to
sampling and processing for paraffin sections in standard
fashion. All tissue sections were stained with hematoxylin
and eosin, with cardiac valves and aorta additionally
stained for elastin and mucin. All sections were examined
by standard light microscopy.
Cell culture
The base medium was a high glucose 1:1 DMEM:F12
(Irvine Scientific). The basal medium (DGA) used for all
other media was the base medium containing glutamine,
penicillin, streptomycin, gentamicin, ciprofloxacin, and
amphotericin as previously described [20]. Medium
(DGF) used for all washes consisted of DGA containing
20% fetal bovine serum.
All procedures were performed as previously described
[20], with modifications. Tissues were quickly thawed,
diluted by drop-wise addition and agitated in 10 volumes
of DGF, then further dissociated by trituration and three
washes in DGF with centrifugation – no enzymatic diges-
tion was used. Whole tissue homogenates were plated
directly on fibronectin-coated tissue culture plates (6-
well, tissue culture treated, Falcon) in primary growth
medium (PGM) composed of DGF containing 10% BITBMC Medical Genetics 2005, 6:2 http://www.biomedcentral.com/1471-2350/6/2
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9500 (Stem Cell Technologies), 40 ng/mL basic fibroblast
growth factor (FGF-2; InVitrogen), 20 ng/mL epidermal
growth factor (EGF; InVitrogen), and 20 ng/mL platelet-
derived growth factor-AB (PDGF-AB; Peprotech). Plates
had been previously incubated with 200 uL/cm2  of
fibronectin (5 ug/mL; Sigma) overnight at 37°C, the
fibronectin solution aspirated, and the plates allowed to
air dry before the introduction of tissue homogenates.
Approximately 300 mg fresh tissue was subjected to minc-
ing and trituration, and the resulting crude tissue
homogenate plated into six wells of a fibronectin-coated
six-well tissue culture plastic plate (≈60 cm2 total surface
area).
After plating, 50% of the medium was replaced, 3 times
weekly. Non-adherent cells and debris from the removed
supernatant were pelleted by centrifugation and re-intro-
duced into the cultures together with the fresh medium.
After 7 days in culture, plates were agitated by sharp rap-
ping with a marking pen and 100% of the culture medium
and non-adherent material was removed. Fifty percent of
the volume removed was replaced with fresh medium,
while the removed medium was centrifuged to pellet cell
debris and non-adherent cells and to recover conditioned
medium as supernatant. Fifty percent, by volume, of the
conditioned medium was then returned to the original
plates. The pellet, containing the non-adherent fraction,
was resuspended in 50% conditioned medium and 50%
fresh medium, by volume, and then transferred to a fresh
fibronectin-coated 6-well plate. After one week, the proce-
dure was repeated, except that the non-adherent fraction
was discarded. In this way, an additional population of
cells was recovered from the non-adherent fraction. All
the cells were eventually combined to form a single pop-
ulation of cultured cells.
At near confluence, cultures were passaged by lifting with
a solution of Cell Dissociation Buffer (GIBCO) supple-
mented with trypsin. The cells were washed twice with
DGF and plated in 1:1 (conditioned:fresh) medium into a
fibronectin-coated T75 flask. Thereafter, and at approxi-
mately one week intervals, cells were lifted and similarly
plated into twice the surface area from which they were
removed. After the cells had reached a confluent surface
area of 600 cm2, the medium from one T75 flask was
exchanged with GM (PGM without serum), and these
cells were cultured for two weeks before immunocyto-
chemical analysis, or differentiation and immunocyto-
chemical analysis, as previously described [20].
Immunocytochemistry
Immunocytochemistry was performed as previously
described [20]. Primary antibodies and dilutions were
used as follows: nestin (1:100; mouse; Chemicon), type
III β-tubulin (Tuj20; 1:100; mouse; Chemicon), MAP2ab
(1:250; mouse; Sigma), GFAP (1:500, guinea pig; Advance
Immuno), CD133-APC (1:100; mouse; Miltenyi), NCAM
(1:100, rabbit, Chemicon), fusin (1:100, mouse, Chemi-
con), and FMRP (1:100; mouse; Chemicon). Coverslips
were mounted with Prolong®  Antifade Kit (Molecular
Probes, Eugene, OR). Some cells were stained with 4',6-
diamidino-2-phenylindole (DAPI, Sigma) before being
rinsed and mounted. Pictures were imaged on an Olym-
pus IX70 Microscope and digitally photographed via a
Microfire digital camera (Optronics, Goleta, CA) using
Image Pro Plus 4.5 with AFA plugin 4.5 software.
Molecular studies
DNA analysis
Genomic DNA was isolated from approximately 5 × 106
neural progenitor cells and from post-mortem sections of
about 500 mg of brain tissue using standard methods
(Puregene Kit; Gentra). For Southern blot analysis, 10 µg
of isolated DNA were digested with EcoRI and NruI. The
FMR1 genomic probe StB12.3, labeled with Dig-11-dUTP
by PCR (PCR dig synthesis Kit, Roche Diagnostics), was
used in the hybridization, as described in Tassone et al.
[31]. Genomic DNA was also amplified by PCR using
primers c and f [32]; PCR products were detected using a
digoxygenin-end-labeled oligonucleotide probe (CGG)10.
Southern blot and PCR analyses were both carried out
using an Alpha Innotech FluorChem 8800 Image Detec-
tion System.
FMR1 mRNA expression levels
Total RNA was isolated from approximately 1 × 106 neural
progenitor cells and from post-mortem brain tissue using
standard methods (Purescript, Gentra Inc. and Trizol).
Reverse transcriptase reactions and quantitative fluores-
cence RT-PCR, using specific primers and probe set for the
FMR1 gene and the control gene (β-glucoronidase; GUS),
were carried out as described in Tassone et al. [33].
Results
Clinical history
JS was a 25-year-old man with fragile X syndrome. His his-
tory included motor and language delays in childhood,
with walking at 20 months, phrases at three years, and
sentences at 6 years of age. He was diagnosed with fragile
X syndrome at 11 years of age, by cytogenetic testing. His
behavior included hyperactivity, anxiety, shyness, poor
eye contact, hand flapping, finger biting, and persevera-
tive speech. At age 24, cognitive testing with the WAIS III
demonstrated a verbal IQ of 58, performance IQ of 51,
and full scale IQ of 51. He did not have autism; childhood
autism rating scale (CARS) score was 28.5 (below autism
range).BMC Medical Genetics 2005, 6:2 http://www.biomedcentral.com/1471-2350/6/2
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Previous medical history included severe mitral valve pro-
lapse; echocardiography revealed moderate thickening
and redundancy of both mitral leaflets, with central mitral
regurgitation (grade 2 to 3+ by Doppler), mild tricuspid
regurgitation, and moderate left ventricular and mild left
atrial enlargement. Upon physical examination at age 24,
JS had a long face, prominent ear pinna, high arched pal-
ate, and macroorchidism with testicular volume of 60 ml
bilaterally. Blood pressure was 142/74, and a grade III/IV
systolic and diastolic murmur with click was heard on
examination. He died unexpectedly at age 25, presumably
due to a cardiac arrhythmia secondary to mitral valve
prolapse.
Pathology
A complete autopsy was performed 16 hours after death.
Abnormal findings included increased brain weight (1600
gm; normal, 1440 ± 20 g), an enlarged heart, (400 gm;
normal, 349 ± 40 g), with features of mitral valve prolapse
(myxomatous thickening of both leaflets; "hooding" of
the posterior leaflet), and increased testicular weight of 73
g (normal average, 25 g). Our laboratory did not receive
the intact brain, but portions of it, therefore detailed gross
and histological evaluation was not possible. In particu-
lar, neither the hippocampus nor the amygdala was avail-
able for histopathological examination. Evaluation of
available brain sections showed diffuse, acute early
ischemic damage corresponding to the manner of death;
no intraneuronal inclusions were seen, nor was there
spongiosis of white matter in the cerebrum, cerebellum,
or middle cerebellar peduncles. Cerebellar folia showed
moderate patchy absence of Purkinje cells; because of the
manner of death, loss due to ischemic damage cannot be
ruled out. However, the majority of Purkinje cells present
appeared histologically normal.
Cell culture
Minced brain tissue, derived from the periventricular zone
in the area of the head of the caudate nucleus and main-
tained under proliferation conditions in serum-contain-
ing medium with growth factors, yielded viable cells that
formed an adherent monolayer on fibronectin-coated
plates. When lifted and plated without serum or fibronec-
tin substrate, the cells grew in suspended clusters/spheres
(Figure 1), similar to previously described neurospheres
[20]. The morphology within the adherent population
was variable and included small, rounded profiles,
medium-sized bipolar and spindle-shaped profiles, and
larger cells with polygonal and multipolar morphologies.
Once a robust primary culture had been established in the
six-well plates (approximately one month after plating of
tissue homogenates), the cultures were passaged into T75
flasks approximately once per week until 600 cm2 of con-
fluent adherent cells had been produced. Cells were then
further expanded under serum-free conditions for immu-
nocytochemical analysis, or under growth-factor-free con-
ditions for biochemical analysis.
Although the methodology used was similar to that previ-
ously reported [20], four conditions employed in the cur-
rent work are noteworthy. (i) The cells were grown from
cryopreserved, rather than fresh, tissue. This modification
allows pathologists with no local access to a stem cell cul-
ture laboratory to preserve tissues for later stem cell har-
vest at a remote collaborating laboratory. (ii) No
enzymatic digestion, only trituration, was used to gener-
ate the crude tissue homogenates. Preliminary studies
showed that enzymatic digestion, typically used with fresh
tissue, adversely affected our ability to harvest living cells
from cryopreserved tissues. (iii) Serum (20%) was main-
tained in the culture until it was expanded to 600 cm2 of
confluent adherent cells, after which the cells were cul-
tured in serum-free medium. Preliminary studies indi-
cated that, unlike cells harvested from fresh tissues, cells
harvested from cryopreserved tissues required application
of serum for a longer time in culture to sustain a sufficient
rate of proliferation. (iv) The non-adherent fraction was
transferred to new fibronectin-coated plates after one
week. Preliminary studies showed that the non-adherent
fraction from cryopreserved tissues retained a significant
population of viable cells for a longer period of time than
that from fresh tissue. These plates were cultured for an
additional week before the remaining non-adherent frac-
tion was finally discarded. Cells grown from both sets of
plates were combined for expansion.
Immunocytochemistry
Immunocytochemical analysis of fragile X neural progen-
itor cells grown under expansion conditions demon-
strated the expression of a range of developmental and
mature neural markers (Figure 2). Many of the current
results are similar to previous findings with control
human neural progenitor cell cultures [20]. In particular,
the distribution of the multipotential neural progenitor
lineage marker, CD133, the neuroepithelial marker nes-
tin, and the neural cell adhesion molecule, NCAM, are
found to be widespread in these cultures, consistent with
earlier observations of immunocytochemistry and flow
cytometry in control human neural progenitor cells
[20,23,24]. The CXCL12 (SDF-1) cytokine receptor,
CXCR4 (fusin, CD184), and the glial neurofilament
marker, glial fibrillary acidic protein (GFAP), are also
widely expressed in the fragile X neural progenitor cell cul-
tures, in agreement with a previous report [20]. The
expression of β-III-tubulin, a mature neuronal marker, is
restricted to subpopulations of cells, again consistent with
control human neural progenitor cells [20]. Finally, the
primitive neuroepithelial (intermediate filament) mark-
ers, nestin and CD133, seen in the proliferating neural
progenitor cells (Figure 2), disappear underBMC Medical Genetics 2005, 6:2 http://www.biomedcentral.com/1471-2350/6/2
Page 5 of 8
(page number not for citation purposes)
differentiation conditions (data not shown). Importantly,
FMRP staining is markedly reduced in the fragile X neural
progenitor cells (Figure 3) compared to control cultures.
Molecular studies
Southern Blot analysis of DNA isolated from brain tissue
(frontal cortex) showed the presence of a mosaic pattern.
Specifically, full mutation alleles were present in 82% of
the cells (435, 528, 652, 727, 847 CGG repeats) with the
remaining 18% harboring a premutation allele. Sizing of
the CGG repeat number by PCR analysis demonstrated
the presence of a premutation allele of 90 CGG repeats
and an allele with the deletion of the CGG element and
the flanking region, the latter of which was not detected
by Southern Blot analysis. Sequence analysis of this allele
indicated the presence of a deletion extending from nucle-
otide 13742 to 13915 of the FMR1 gene (GenBank acces-
sion number L29074). Southern blot analysis of DNA
isolated from neural progenitor cells revealed the presence
only of hypermethylated full mutation alleles (536 and
591 CGG repeats). No premutation alleles were detected
by PCR analysis.
The brain FMR1 mRNA level (frontal cortex) relative to
the reference gene (glucuronidase) was low (0.08 ± 0.009,
relative value). In agreement with the observed lack of
FMRP expression, no FMR1 message was detected after 40
cycles of PCR in total RNA isolated from the neural pro-
genitor cells.
Discussion
In the current work, we have successfully isolated and cul-
tured neural progenitor cells from post-mortem brain tis-
sue of an adult male with fragile X syndrome, which, to
our knowledge, is the first example of the production of
adult, human neural progenitor cells for any neurodevel-
opmental disorder. This result is of particular importance
for the study of fragile X syndrome, since the disease-caus-
ing CGG repeat expansions have thus far been refractory
to cloning into any animal or human cell model. With
these cells, we hope to better understand the mechanistic
link between the CGG expansion and the disease pheno-
type, which is known for the donor of the cells.
We have demonstrated the feasibility of generating neural
progenitor cell cultures from post-mortem brains of
patients with neurogenetic disease. Moreover, as the cul-
tures were generated from cryopreserved tissue, our data
suggest that cells can be harvested and processed from the
required tissues in locations that are remote from the stem
cell culture laboratory. This last point is of particular
importance for the study of neurogenetic diseases, which
generally affect only 1:20,000 to 1:200,000 live births; a
technique that can be implemented at multiple
Phase-contrast photomicrographs of fragile X progenitor  cells Figure 1
Phase-contrast photomicrographs of fragile X pro-
genitor cells The figure shows clusters/spheres during the 
initial stages (2–3 days after plating) of adherence to a 
fibronectin substrate. (A) 4×; (B) 10×; (C) 20×. Confluent 
serum- and growth factor-expanded cultures were serum 
deprived for one week in the presence of growth factors, 
then lifted with enzyme-free buffers and transferred to new 
plates with no fibronectin substrate. After growing the 
resulting clusters/spheres for two weeks, the clusters/
spheres were transferred to new fibronectin-coated plates. 
Clusters/spheres (black arrows) are abundant and are seen 
adhering to the substrate. Cells (black arrowheads) can be 
seen streaming from the spheres and spreading out on the 
substrate.BMC Medical Genetics 2005, 6:2 http://www.biomedcentral.com/1471-2350/6/2
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Staining of fragile X progenitor cells, grown under expansion conditions Figure 2
Staining of fragile X progenitor cells, grown under expansion conditions In all panels, nuclei are stained with DAPI 
(blue), while the second color represents antibody staining as follows: (A) multipotential neural progenitor lineage marker, 
CD133 (red); (B) neural cell adhesion molecule, NCAM (green); (C) CXCL12 (SDF-1) cytokine receptor, CXCR4 (fusin, 
CD184, red); (D) β-III-tubulin (green); (E) the glial fibrillary acidic protein, GFAP (green); (F) nestin. (100×).BMC Medical Genetics 2005, 6:2 http://www.biomedcentral.com/1471-2350/6/2
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institutions will be necessary to generate sufficient num-
bers of specimens for statistical analysis.
A major determinant of the proliferative capacity of neural
progenitor cells in culture is donor age, with younger
donors (particularly fetuses and infants) having greater
proliferative capacity than adults [18]. Although progeni-
tor cells can be obtained from fetal or embryonic sources,
there are advantages to obtaining cells from post-mortem
adult tissue. In using cells derived from adult tissues, one
avoids the serious ethical controversies surrounding the
use of fetal samples [25-27]. Moreover, for research aimed
at understanding the effects of identified genetic defects
on neural development, the phenotypic expression of a
particular neurogenetic disease can be ascertained with
post-mortem specimens, thus making a correlation possi-
ble between in vitro and in vivo pathophysiology. Due to
the broad variability in phenotypic expression in fragile X
syndrome (as with many other neurodevelopmental dis-
orders), any such correlations are problematic using tissue
obtained at fetopsy.
The method used to isolate the neural progenitor cells in
the current study was adapted from the neuro-selective
methods developed for culturing CNS stem cells from the
brain [28], spinal cord [29], and retina [30] of rodents, as
well as the brain of humans [18,20]. Passaged cells
expressed a number of immature markers, including the
neural stem cell markers CD133 and nestin [20].
Although the currently recognized method for establish-
ing multipotency is clonal derivation followed by differ-
entiation, these cells proliferated poorly when seeded at
low density and, therefore, clonal derivation has not been
fruitful thus far. Nevertheless, analysis of marker expres-
sion provides evidence that these cultures give rise to cells
of neuronal lineage (β-III tubulin) and glial lineage
(GFAP). Our data are thus most consistent with the inter-
pretation that the immature, highly proliferative neuroep-
ithelial cells in the present study were multipotent neural
progenitor cells.
Conclusions
The successful production of neural cells from an individ-
ual with fragile X syndrome opens a new avenue for the
scientific study of the molecular basis of this disorder, as
well as an approach for studying the efficacy of new ther-
apeutic agents.
Markedly reduced staining with anti-FMRP antibody of neural progenitor cells from a fragile X patient Figure 3
Markedly reduced staining with anti-FMRP antibody of neural progenitor cells from a fragile X patient FMRP 
staining (green) is greatly reduced in the fragile X derived cells (A) relative to progenitor cells from an unaffected control (B). 
Cell nuclei counterstained with DAPI (blue); both panels, 40×.BMC Medical Genetics 2005, 6:2 http://www.biomedcentral.com/1471-2350/6/2
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